| Financier | Commitments |
|---|---|
| International Bank for Reconstruction and Development | 1000.00 |
COVID-19 Financial Access DPF
Abstract*
The development objective of COVID-19 Financial Access Development Policy Financing Program aims to: (i) support liquidity in the financial sector; and (ii) establish instruments for improved financial access. Insufficient financial inclusion and lack of access to credit are some of the factors contributing to low growth and limited poverty reduction in Mexico, as highlighted by the Systematic Country Diagnostic (SCD) and the government’s own assessment... Show More
Development Objective
Contribute to the government’s efforts to: (i) support liquidity in the financial sector, and (ii) establish instruments for improved financial access.
Key Details
Project Details
P172863
Closed
Eva Gutierrez
United Mexican States
January 31, 2020
(as of board presentation)
May 19, 2020
May 28, 2020
US$ 0.00 million
Ministry of Finance and Public Credit (Secretaría de Hacienda y Crédito Público)
2020
US$ 1000.00 million
N/A
May 31, 2022
May 31, 2021
BANK APPROVED
Finances
Financing Plan (US$ Millions)
Total Project Financing (US$ Millions)
| Product Line | IBRD/IDA |
|---|---|
| IBRD Commitment | 1000.00 |
| IDA Commitment | N/A |
| IBRD + IDA Commitment | 1000.00 |
| Lending Instrument | |
|---|---|
| Grant Amount | N/A |
| Total Project Cost** | N/A |
Summary Status of World Bank Financing (US$ Millions) as of March 31, 2025
No data available.
| Period | Financier | Transaction Type | Amount (US$) |
|---|---|---|---|
| Mar 15, 2024 | IBRD-91040 | Int Charges | 1,282.69 |
| Mar 15, 2024 | IBRD-91040 | Int Charges | 511,792.34 |
| Mar 15, 2024 | IBRD-91040 | Int Charges | 79,764.61 |
| Mar 15, 2024 | IBRD-91040 | Int Charges | 31,826,080.00 |
| May 19, 2020 | IBRD-91040 | Loan Commitment | 1,000,000,000.00 |
| Sep 15, 2023 | IBRD-91040 | Int Charges | 954.84 |
| Sep 15, 2023 | IBRD-91040 | Int Charges | 380,982.75 |
| Sep 15, 2023 | IBRD-91040 | Int Charges | 71,687.62 |
| Sep 15, 2023 | IBRD-91040 | Int Charges | 28,603,362.00 |
| May 28, 2020 | IBRD-91040 | Fee Charges | 2,500,000.00 |
| May 28, 2020 | IBRD-91040 | Loan Disb | 2,500,000.00 |
| Mar 15, 2021 | IBRD-91040 | Int Charges | 211,219.27 |
| Mar 15, 2021 | IBRD-91040 | Int Charges | 3,657,500.00 |
| Mar 15, 2021 | IBRD-91040 | Int Charges | 11,061.11 |
| Mar 15, 2021 | IBRD-91040 | Loan Disb | -997,500,030.00 |
| Mar 15, 2021 | IBRD-91040 | Loan Disb | 997,500,030.00 |
| Sep 15, 2020 | IBRD-91040 | Int Charges | 9,701.39 |
| Sep 15, 2020 | IBRD-91040 | Int Charges | 337,788.38 |
| Sep 15, 2020 | IBRD-91040 | Int Charges | 9,701.39 |
| Oct 16, 2020 | IBRD-91040 | Loan Disb | 997,500,030.00 |
| Sep 15, 2020 | IBRD-91040 | Loan Disb | -2,500,000.00 |
| Sep 15, 2020 | IBRD-91040 | Loan Disb | 2,500,000.00 |
| Sep 15, 2021 | IBRD-91040 | Int Charges | 4,129,650.00 |
| Sep 15, 2021 | IBRD-91040 | Int Charges | 10,350.00 |
| Mar 15, 2022 | IBRD-91040 | Int Charges | 9,804.17 |
| Mar 15, 2022 | IBRD-91040 | Int Charges | 3,911,862.50 |
| Sep 15, 2022 | IBRD-91040 | Int Charges | 22,184.92 |
| Sep 15, 2022 | IBRD-91040 | Int Charges | 8,851,783.00 |
| Mar 15, 2023 | IBRD-91040 | Int Charges | 2,851.49 |
| Mar 15, 2023 | IBRD-91040 | Int Charges | 1,137,744.40 |
| Mar 15, 2023 | IBRD-91040 | Int Charges | 61,817.72 |
| Mar 15, 2023 | IBRD-91040 | Int Charges | 24,665,270.00 |
Ratings
IMPLEMENTATION RATINGS
No data available.
COMPLETION RATINGS
| INDICATOR | IMPLEMENTATION COMPLETION & RESULTS REPORT: 06-02-2022 |
|---|---|
| Outcomes | Substantial |
| Risk to Development Outcome | |
| Bank Performance | Moderately Satisfactory |
| Borrower Performance | |
| Government Performance | |
| Implementing Agency |
INDEPENDENT EVALUATION RATINGS
| INDICATOR | ICR REVIEW: 03-22-2023 | PROJECT PERFORMANCE ASSESSMENT REPORT: |
|---|---|---|
| Outcome Rating | Satisfactory | N/a |
| Risk To Development Outcome | N/a | |
| Bank Performance | Moderately Satisfactory | N/a |
| Borrower Performance | N/a | |
| Government Performance | N/a | |
| Implementing Agency | N/a | |
| Icr Quality | Substantial | N/a |
| M&e Quality | N/a |
Results Framework
No data available.